Related Experiment Video
Updated: Mar 11, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?
Klaus Geissler1, Eva Jäger2, Agnes Barna3
15 Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria klaus.geissler@wienkav.at.
No abstract available in PubMed .
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Related Concept Videos
Abnormal Proliferation
The Ras Gene
Ras is a...
Targeted Cancer Therapies
There are several types of targeted therapies against...
The JAK-STAT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity: